A pilot study of low-dose subcutaneous alemtuzumab therapy for patients with hemotherapy-refractory chronic lymphocytic leukemia

Haematologica

Volumn 90, Issue 3, 2005, Pages 410-412

  Cortelezzi, Agostino ^a,c   Pasquini, Maria Cristina ^c   Sarina, Barbara ^b   Bertani, Giambattista ^c   Grifoni, Federica ^c   Colombi, Mariangela ^c   Deliliers, Giorgio Lambertenghi ^a,c  

^a UNIVERSITY OF MILAN   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Alemtuzumab; Autoimmune hemolytic anemia; B CLL; Complete response; HBV; Overall response; Safety

Indexed keywords

ALEMTUZUMAB; FLUDARABINE; RITUXIMAB;

ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CYTOGENETICS; DRUG RESPONSE; FEMALE; HUMAN; LOW DRUG DOSE; MALE; PILOT STUDY; PROGNOSIS; STAGING;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MIDDLE AGED; PILOT PROJECTS; REMISSION INDUCTION; SALVAGE THERAPY;

EID: 15244362778     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Osterborg A, Dyer MJ, Bunjes D, Pangalis GA, Bastion Y, Catovsky D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia: European Study Group of Alemtuzumab-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 1997; 15:1567-74.
2. Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, et al. Therapeutic role of alemtuzumab (campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:3554-61.
3. Rai KR, Freter CE, Mercier RJ, Cooper MR, Mitchell BS, Stadtmauer EA, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002;20:3891-7.
4. Keating MJ, O'Brien S, Kontoyiannis D, Plunkett W, Koller C, Beran M, et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leukemia Lymphoma 2002;43:1755-62.
5. Keating M, Coutre S, Rai K, Osterborg A, Faderl S, Kennedy B, et al. Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin Lymphoma 2004;4:220-7.
6. Wendtner CM, Ritgen M, Schweighofer CD, Fingerle-Rowson G, Campe H, Jager G, et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission - experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 2004;18:1093-101.
7. O'Brien SM, Kantarjian HM, Thomas DA, Cortes J, Giles FJ, Wierda WG, et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 2003;98:2657-63.
8. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, et al. National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990-7.
9. Rawstron AC, Kennedy B, Moreton P, Dickinson AJ, Cullen MJ, Richards SJ, et al. Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia. Blood 2004;103:2027-31.
10. Heider U, Fleissner C, Zavrski I, Jakob C, Dietzel T, Eucker J, et al. Treatment of refractory chronic lymphocytic leukemia with campath 1H in combination with lamivudine in chronic hepatitis B infection. Eur J Haematol 2004;72:64-6.